贝伐珠单抗联合腹腔热灌注化疗对卵巢癌患者APE1／Ref-1基因表达的影响  

Effect of Intraperitoneal Bevacizumab Combined with lntraperitoneal Hyperthermic Perfusion Chemotherapy on APE1/Ref-1 Gene Expression in Ovarian Cancer Patients

作　　者：李少星[1] 

机构地区：[1]成都医学院第一附属医院,四川成都610500

出　　处：《医学临床研究》2017年第3期453-455,458,共4页Journal of Clinical Research

摘　　要：[目的]探讨贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌患者的疗效及对APE1／Ref-1基因表达的影响。[方法]取卵巢癌患者80例，根据治疗方法不同分为对照纽和观察组，每组40例。两组患者均给予紫杉醇联合卡铂化疗，对照组采用腹腔热灌注化疗治疗，观察组在对照组基础上联合腹腔内贝伐珠单抗治疗，比较两组临床疗效及对APE1／Ref-1基因表达的影响。[结果]观察组有效率为90．00％（36／40），明显高于对照组67．50％（27／40），其差异有统计学意义（P〈0．05）；观察组患者治疗4周后不良反应发生率为15．00％（6／40），与对照组17．50％（7／40）比较差异无统计学意义（P〉0．05）；Western blot结果显示：观察组治疗后APE1／Ref-1基因表达量显著增高，显著高于对照组APEl／Ref-1基因表达量（P〈0．05）。[结论]贝伐珠单抗合并用于腹腔热灌注化疗治疗卵巢癌患者，疗效满意，治疗时APE1／Ref-1基因表达明显增强，有助于提高化疗敏感性，值得推广应用。[Objective]To explore the application of intraperitoneal bevacizumah （abdominal Neiheifazhu mon-oclonal antibody） combined with intraperitoneal hyperthermic perfusion chemotherapy in ovarian cancer patients and to detect the changes of APE1/Ref-1 gene expression before and after the treatment. [Methods]Eighty cases of ovarian cancer were randomly divided into control group （ n = 40） and observation group （ n = 40）. Two groups of patients were treated with paelitaxel and carboplatin chemotherapy. Patients in the control group received intraper-itoneal hyperthermic perfusion chemotherapy treatment, and patients in the observation group received intraperito- neal hyperthermie perfusion chemotherapy combined with intraperitoneal bevacizumab （Neibeifazhu monoclonal antibody）. The clinical efficacy and APE1/Ref-1 gene expression were compared between the two groups.[Results] After 4 weeks of treatment, the curative effect of the observation group was 90%, which was higher than that of the control group （67.50%）, and the difference was significant （ P〈0.05）. The adverse reaction rate had no sig- nificant difference between the observation group （6/40, 15 %） and control group（7/40,17.5%） （ P〉0.05）. Real-time PCR showed that APE1/Ref-1 gene expression was significantly increased after treatment in the two groups compared to that before treatment. The changes of APE-1/Ref-1 expression level in the observation group was significantly higher than that in the control group （ P〈0.05）. [Conclusion]Compared to intraperitoneal hy- perthermic perfusion alone, the clinical effect of bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in ovarian cancer patients is better. During this combo treatment, APE1/Ref-1 gene expression was significantly enhanced in ovarian cancer tissues to improve the sensitivity to chemotherapy. It is worthy of popularization and application.

关 键 词：抗体 单克隆 高温 诱发 腹腔 卵巢肿瘤/治疗 基因表达 

分 类 号：R737.31[医药卫生—肿瘤]